{"id":3667,"date":"2024-08-02T16:40:09","date_gmt":"2024-08-02T16:40:09","guid":{"rendered":"https:\/\/longchangextracts.com\/?p=3667"},"modified":"2024-08-02T16:40:09","modified_gmt":"2024-08-02T16:40:09","slug":"ganoderma-lucidum-polysaccharide-diabetic-nephropathy","status":"publish","type":"post","link":"https:\/\/longchangextracts.com\/tr\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/","title":{"rendered":"Ganoderma Polisakkaritinin Diyabet Nefropatili Fareler \u00dczerindeki \u0130yile\u015ftirici Etkisi ve Mekanizmas\u0131 \u00dczerine \u00c7al\u0131\u015fma"},"content":{"rendered":"

Ganoderma Polisakkaritinin Diyabet Nefropatili Fareler \u00dczerindeki \u0130yile\u015ftirici Etkisi ve Mekanizmas\u0131 \u00dczerine \u00c7al\u0131\u015fma
\nDiyabet nefropatisi (DN), diyabet hastalar\u0131nda en s\u0131k g\u00f6r\u00fclen mikrovask\u00fcler komplikasyonlardan biridir. DN'nin b\u00f6brek fonksiyonlar\u0131nda yol a\u00e7t\u0131\u011f\u0131 hasar, d\u00fcnya \u00e7ap\u0131nda sakatl\u0131k ve \u00f6l\u00fcmlerin ba\u015fl\u0131ca nedenlerinden biridir. Son birka\u00e7 on y\u0131lda DN tedavisinde baz\u0131 ilerlemeler kaydedilmesine ra\u011fmen, hala bir dizi zorluk bulunmaktad\u0131r. Geleneksel tedavi y\u00f6ntemleri genellikle sadece kan \u015fekeri ve kan bas\u0131nc\u0131n\u0131 kontrol alt\u0131na alarak hastal\u0131\u011f\u0131n ilerlemesini yava\u015flatmakta, etkili bir \u015fekilde iyile\u015ftirememekte veya tersine \u00e7evirememektedir. Ayr\u0131ca, baz\u0131 hastalarda mevcut tedavi y\u00f6ntemlerine kar\u015f\u0131 diren\u00e7 veya olumsuz reaksiyonlar geli\u015febilmektedir, bu nedenle yeni tedavi stratejilerinin bulunmas\u0131na acil ihtiya\u00e7 vard\u0131r.
\nLingzhi, Asya'da ve di\u011fer b\u00f6lgelerde geleneksel \u00c7in t\u0131bb\u0131 tedavilerinde yayg\u0131n olarak kullan\u0131lan geleneksel bir \u00c7in bitkisidir. Ana etkili bile\u015fenlerinden biri Ganoderma lucidum polisakkaritidir (GLP). Geleneksel \u00c7in t\u0131bb\u0131 Ganoderma lucidum'dan elde edilen do\u011fal etkili bir bile\u015fen olan GLP'nin, ba\u011f\u0131\u015f\u0131kl\u0131k fonksiyonunu art\u0131rma, anti-t\u00fcm\u00f6r, antioksidan vb. gibi farmakolojik aktiviteleri nedeniyle diyabet ve komplikasyonlar\u0131n\u0131n tedavisinde potansiyel bir rol oynayabilece\u011fi d\u00fc\u015f\u00fcn\u00fclmektedir. Ara\u015ft\u0131rmalar, GLP'nin etkilerini ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin d\u00fczenlenmesi, anti-enflamatuar ve antioksidan etkiler de dahil olmak \u00fczere \u00e7e\u015fitli yollarla g\u00f6sterebilece\u011fini g\u00f6stermi\u015ftir. Bu aktif bile\u015fenler, laboratuvar ara\u015ft\u0131rmalar\u0131nda ve klinik uygulamalarda, \u00f6zellikle diyabetle ilgili hastal\u0131klar\u0131n tedavisinde belirli bir terap\u00f6tik potansiyel g\u00f6stermi\u015ftir. Bu \u00f6zellikler GLP'yi DN tedavisi i\u00e7in umut verici bir do\u011fal ila\u00e7 haline getirmektedir.
\nDiyabetik nefropatinin geli\u015fim s\u00fcrecinde, ileri glikasyon son \u00fcr\u00fcnleri i\u00e7in resept\u00f6r (RAGE), kolajen tip IV (COL-IV) ve ind\u00fcklenebilir nitrik oksit sentaz (iNOS) ekspresyon de\u011fi\u015fiklikleri \u00f6nemli bir rol oynamaktad\u0131r. RAGE, diyabetin \u00e7e\u015fitli komplikasyonlar\u0131n\u0131n molek\u00fcler bir arac\u0131s\u0131 olarak, aktivasyonu enflamatuar reaksiyonu ve oksidatif stresi \u015fiddetlendirebilir ve b\u00f6brek hasar\u0131n\u0131 te\u015fvik edebilir. COL-IV, glomer\u00fcler bazal membran\u0131n \u00f6nemli bir bile\u015fenidir ve anormal birikimi glomer\u00fcloskleroz ile ili\u015fkilidir. iNOS'un a\u015f\u0131r\u0131 ekspresyonu renal inflamasyon ve h\u00fccre apoptozu ile yak\u0131ndan ili\u015fkilidir. Bu nedenle, bu proteinlerin ekspresyonunu tespit etmek DN'nin patolojik ilerlemesini anlamak i\u00e7in \u00e7ok \u00f6nemlidir ve yeni terap\u00f6tik hedefleri ke\u015ffetme imkan\u0131 sa\u011flar.<\/p>\n

\"\"\"\"\"\"\"\"\"\"\"\"\"\"
\nGLP'nin DN \u00fczerindeki potansiyel terap\u00f6tik etkisini de\u011ferlendirmek i\u00e7in, streptozotosin (STZ) ile ind\u00fcklenmi\u015f DN fare modeli ile birlikte y\u00fcksek ya\u011fl\u0131 bir diyet kullan\u0131lm\u0131\u015f ve etki mekanizmas\u0131 ara\u015ft\u0131r\u0131lm\u0131\u015ft\u0131r. Bu nedenle, bir aminoguanidin grubu \u00f6zel olarak pozitif kontrol olarak belirlenmi\u015ftir. GLP'nin etkinli\u011fini aminoguanidin ile kar\u015f\u0131la\u015ft\u0131rarak, GLP'nin DN tedavisindeki potansiyeli ve etkinli\u011fi \u00f6nceden de\u011ferlendirilebilir. A\u00e7l\u0131k kan \u015fekeri (FBG), yemek yedikten sonra (genellikle 8-12 saat) a\u00e7l\u0131k durumunda \u00f6l\u00e7\u00fclen kan \u015fekeri seviyesidir ve genellikle diyabetin tan\u0131 ve y\u00f6netimini de\u011ferlendirmek i\u00e7in kullan\u0131l\u0131r. 24 saatlik idrar toplam proteini (24 saatlik UTP), 24 saat i\u00e7inde idrar yoluyla at\u0131lan toplam protein miktar\u0131d\u0131r. Diyabetik nefropati gibi b\u00f6brek hastal\u0131klar\u0131 incelenirken, idrarla glukoz at\u0131l\u0131m\u0131ndaki art\u0131\u015f glomer\u00fcler filtrasyon membran\u0131ndaki hasar\u0131 yans\u0131tabilir. Kan \u00fcre azotu (BUN) kandaki \u00fcre azotu konsantrasyonudur ve bu seviyedeki bir art\u0131\u015f b\u00f6brek filtrasyon fonksiyonunda azalma, b\u00f6brek hastal\u0131\u011f\u0131, dehidrasyon, y\u00fcksek proteinli diyet ve di\u011fer fakt\u00f6rlerin varl\u0131\u011f\u0131na i\u015faret edebilir. Serum kreatinin olarak da bilinen serum kreatinin (Scr), glomer\u00fcler filtrasyon h\u0131z\u0131n\u0131 de\u011ferlendirmek i\u00e7in yayg\u0131n olarak bir g\u00f6sterge olarak kullan\u0131l\u0131r. Y\u00fcksek Scr seviyeleri b\u00f6brek fonksiyonlar\u0131n\u0131n azald\u0131\u011f\u0131n\u0131 g\u00f6sterebilir. B\u00f6breklerdeki patolojik de\u011fi\u015fiklikleri ve ilgili proteinlerin ekspresyon d\u00fczeylerini FBG, 24 saatlik UTP, BUN ve Scr d\u00fczeylerinin yan\u0131 s\u0131ra histolojik ve molek\u00fcler biyoloji y\u00f6ntemleriyle tespit ederek de\u011ferlendirece\u011fiz. GLP'nin RAGE sinyal yola\u011f\u0131n\u0131 inhibe ederek DN geli\u015fimini iyile\u015ftirebilece\u011fini d\u00fc\u015f\u00fcn\u00fcyoruz. Bu \u00e7al\u0131\u015fman\u0131n geli\u015ftirilmesi, DN tedavisindeki mevcut bilgi bo\u015flu\u011funun doldurulmas\u0131na yard\u0131mc\u0131 olacak ve gelecekteki klinik uygulamalar i\u00e7in teorik ve pratik bir temel sa\u011flayacakt\u0131r. Ayn\u0131 zamanda, bu \u00e7al\u0131\u015fma diyabet ve komplikasyonlar\u0131n\u0131 tedavi etmek i\u00e7in daha geni\u015f bir do\u011fal ila\u00e7 yelpazesini ke\u015ffetmek i\u00e7in yeni bir y\u00f6n ve olas\u0131l\u0131k da sa\u011flamaktad\u0131r.
\nDN, diyabet hastalar\u0131nda en s\u0131k g\u00f6r\u00fclen komplikasyonlardan biridir ve olu\u015fumu esas olarak uzun s\u00fcreli hipergliseminin neden oldu\u011fu glomer\u00fcl ve renal t\u00fcb\u00fcllerin hasar\u0131yla ilgilidir. DN'nin geli\u015fimi s\u0131ras\u0131nda, diyabetin neden oldu\u011fu metabolik anormallikler ve enflamatuar reaksiyonlar b\u00f6brek dokusunun yap\u0131s\u0131nda ve i\u015flevinde de\u011fi\u015fikliklere yol a\u00e7ar ve sonu\u00e7ta b\u00f6brek yetmezli\u011fine neden olur. Bu nedenle, diyabetik nefropatinin ilerlemesini kontrol alt\u0131na almak i\u00e7in etkili tedavi y\u00f6ntemleri bulmak \u00e7ok \u00f6nemlidir. GLP, Ganoderma lucidum h\u00fccrelerinden elde edilen, antioksidan, anti-enflamatuar ve anti-t\u00fcm\u00f6r etkileri dahil olmak \u00fczere \u00e7e\u015fitli biyolojik aktivitelere sahip bir polisakkarit bile\u015fi\u011fidir. Son \u00e7al\u0131\u015fmalar, GLP'nin diyabet ve komplikasyonlar\u0131n\u0131n tedavisinde belirli bir potansiyele sahip oldu\u011funu, inflamatuar yan\u0131t\u0131 d\u00fczenleyerek, oksidatif stresi inhibe ederek ve h\u00fccresel sinyal yollar\u0131n\u0131 iyile\u015ftirerek rol oynayabilece\u011fini g\u00f6stermi\u015ftir. Bu \u00e7al\u0131\u015fmada AG grubu, ara\u015ft\u0131rman\u0131n bilimsel ge\u00e7erlili\u011fini ve inand\u0131r\u0131c\u0131l\u0131\u011f\u0131n\u0131 art\u0131rmak i\u00e7in \u00f6zellikle pozitif kontrol olarak kullan\u0131lm\u0131\u015ft\u0131r. Yayg\u0131n olarak tan\u0131nan bir anti diyabet ilac\u0131 olan AG, DN \u00fczerindeki terap\u00f6tik etkisi ve mekanizmas\u0131 konusunda net bir bilimsel kayda sahiptir. GLP'nin terap\u00f6tik etkisini AG ile do\u011frudan kar\u015f\u0131la\u015ft\u0131rarak, sadece GLP'nin etkinlik \u00f6l\u00e7\u00fct\u00fc olu\u015fturulmakla kalmaz, ayn\u0131 zamanda DN tedavisindeki etki mekanizmas\u0131 da derinlemesine anla\u015f\u0131labilir. Buna ek olarak, AG grubunun ortam\u0131, herhangi bir yeni ilac\u0131n klinik \u00e7evirisi i\u00e7in \u00e7ok \u00f6nemli olan GLP'nin g\u00fcvenli\u011finin ve tolere edilebilirli\u011finin de\u011ferlendirilmesine de olanak tan\u0131r. Bu kar\u015f\u0131la\u015ft\u0131rma sayesinde, GLP'nin yeni ve etkili bir tedavi se\u00e7ene\u011fi haline gelip gelemeyece\u011fi veya tedavi etkinli\u011fini art\u0131rmak i\u00e7in AG ile birlikte kullan\u0131l\u0131p kullan\u0131lamayaca\u011f\u0131 ara\u015ft\u0131r\u0131lmaktad\u0131r. Nihayetinde, bu bulgular gelecekteki ara\u015ft\u0131rma y\u00f6nelimleri i\u00e7in de\u011ferli bilgiler sa\u011flayacak ve klinik uygulamada DN tedavi stratejilerinin optimizasyonuna rehberlik edebilecektir.
\nBu \u00e7al\u0131\u015fman\u0131n amac\u0131, STZ ile kombine edilmi\u015f y\u00fcksek ya\u011fl\u0131 diyetle ind\u00fcklenen DN fareler \u00fczerinde GLP'nin etkilerini ve potansiyel mekanizmalar\u0131n\u0131 ara\u015ft\u0131rmakt\u0131r. Bir dizi deneyle, kontrol grubuyla kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, DN grubu farelerde FGB, 24 saatlik UTP, BUN ve Scr seviyelerinin \u00f6nemli \u00f6l\u00e7\u00fcde artt\u0131\u011f\u0131n\u0131 ve b\u00f6brek patolojik hasar\u0131 ve fibrozis derecesinin \u00f6nemli \u00f6l\u00e7\u00fcde a\u011f\u0131rla\u015ft\u0131\u011f\u0131n\u0131 bulduk. Ayn\u0131 zamanda, b\u00f6brek dokusundaki TNF - \u03b1 ve IL-6 seviyeleri de artarken, anti-inflamatuar fakt\u00f6r IL-10 seviyesi azalm\u0131\u015ft\u0131r. AG grubu ve DN+GLP grubu farelerin b\u00f6brek patolojik hasar\u0131 ve fibrozis derecesi \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015fmi\u015f ve ilgili kantitatif g\u00f6stergeler de \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015fmi\u015ftir. Ayr\u0131ca, DN farelerinde RAGE, COL-IV ve iNOS proteinlerinin ekspresyonunda \u00f6nemli art\u0131\u015flar g\u00f6zlenmi\u015ftir; bu da DN'nin patolojik \u00f6zellikleriyle uyumludur ve bu proteinlerin DN geli\u015fiminde \u00f6nemli roller oynad\u0131\u011f\u0131n\u0131 d\u00fc\u015f\u00fcnd\u00fcrmektedir. GLP m\u00fcdahalesinden sonra, bu proteinlerin ekspresyon seviyelerinin \u00f6nemli \u00f6l\u00e7\u00fcde a\u015fa\u011f\u0131 reg\u00fcle edildi\u011fi bulunmu\u015ftur; bu da GLP'nin bu anahtar proteinlerin ekspresyonunu inhibe ederek DN'nin patolojik ilerlemesini yava\u015flatabilece\u011fini g\u00f6stermektedir. RAGE'nin a\u015fa\u011f\u0131 reg\u00fclasyonu inflamasyonu ve oksidatif stresi azaltabilirken, COL-IV'\u00fcn azalmas\u0131 glomer\u00fclosklerozun hafifletilmesine yard\u0131mc\u0131 olabilir. Bu arada, iNOS ekspresyonundaki azalma renal inflamasyon ve h\u00fccre apoptozu s\u00fcrecini yava\u015flatabilir. Bu sonu\u00e7lar, RAGE, COL-IV ve iNOS protein ekspresyonunun GLP taraf\u0131ndan d\u00fczenlenmesinin, DN'yi iyile\u015ftirmek i\u00e7in anahtar mekanizmalar\u0131ndan biri olabilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrmektedir. Yukar\u0131daki sonu\u00e7lar, GLP'nin DN fareleri \u00fczerinde belirli bir derecede iyile\u015ftirici etkiye sahip oldu\u011funu ve GLP'nin koruyucu etkisini RAGE sinyal yolunu inhibe ederek elde edebilece\u011fini g\u00f6stermektedir. Deneysel sonu\u00e7lar, GLP'nin DN farelerinde b\u00f6brek patolojik hasar\u0131 ve fibrozis derecesini \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirebilece\u011fini, diyabetle ilgili biyokimyasal g\u00f6stergeleri azaltabilece\u011fini ve RAGE sinyal yolunu inhibe ederek koruyucu rol\u00fcn\u00fc oynayabilece\u011fini g\u00f6stermektedir. Bu nedenle, GLP DN i\u00e7in potansiyel bir tedavi olabilir ve mekanizmas\u0131 anti-enflamatuar, antioksidan ve anti fibrotik etkiler gibi \u00e7oklu biyolojik etkileri i\u00e7erebilir. Gelecekteki ara\u015ft\u0131rmalar, GLP'nin bu proteinlerin ekspresyonu \u00fczerindeki d\u00fczenleyici mekanizmalar\u0131n\u0131 ve bu yolaklar arac\u0131l\u0131\u011f\u0131yla DN'ye nas\u0131l etkili bir \u015fekilde m\u00fcdahale edilebilece\u011fini daha fazla ara\u015ft\u0131rabilir.
\nElbette bu \u00e7al\u0131\u015fmada baz\u0131 eksiklikler de bulunmaktad\u0131r. \u0130lk olarak, ara\u015ft\u0131rmalar GLP'nin enflamatuar yan\u0131tlar\u0131 d\u00fczenleme mekanizmas\u0131n\u0131n daha derin bir analizini sa\u011flayabilir. Enflamatuar yan\u0131t DN geli\u015fiminde \u00f6nemli bir rol oynar ve GLP enflamatuar arac\u0131lar\u0131n sal\u0131n\u0131m\u0131n\u0131 engelleyerek veya enflamatuar sinyal yollar\u0131n\u0131n aktivitesini d\u00fczenleyerek b\u00f6brek enflamasyonunu hafifletebilir, b\u00f6ylece b\u00f6brek dokusunu hasardan koruyabilir. \u0130kinci olarak, ara\u015ft\u0131rmalar GLP'nin renal fibrozis \u00fczerindeki d\u00fczenleyici mekanizmas\u0131n\u0131 ke\u015ffedebilir. Diyabetik nefropatinin geli\u015fimi s\u0131ras\u0131nda, b\u00f6brek dokusunun fibrozisi, b\u00f6brek fonksiyon bozuklu\u011funa ve hastal\u0131\u011f\u0131n ilerlemesine yol a\u00e7an ana fakt\u00f6rlerden biridir. GLP, kolajen sentezini inhibe ederek, matris metaloproteinaz aktivitesini d\u00fczenleyerek veya kolajen degradasyonunu te\u015fvik ederek renal fibrozu hafifletebilir, b\u00f6ylece b\u00f6brek yap\u0131s\u0131 ve fonksiyonunun b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc koruyabilir. Ayr\u0131ca, DN tedavisinde GLP'nin potansiyel klinik uygulama olanaklar\u0131n\u0131 ara\u015ft\u0131rmak da \u00f6nemlidir. Mevcut ara\u015ft\u0131rmalar esas olarak hayvan modellerine odaklansa da, sonu\u00e7lar DN tedavisinde potansiyel bir ila\u00e7 olarak GLP i\u00e7in g\u00fc\u00e7l\u00fc bir destek sa\u011flamaktad\u0131r. Daha ileri klinik \u00e7al\u0131\u015fmalar, GLP'nin insan DN tedavisindeki g\u00fcvenli\u011fini ve etkinli\u011fini belirlemeye yard\u0131mc\u0131 olacakt\u0131r. Son olarak, ara\u015ft\u0131rmac\u0131lar diyabetik nefropati tedavisinde GLP ve aminoguanidinin avantaj ve dezavantajlar\u0131n\u0131 kar\u015f\u0131la\u015ft\u0131rabilirler. Geleneksel ila\u00e7larla kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131nda, GLP daha geni\u015f bir biyolojik aktivite yelpazesine ve daha az yan etkiye sahip olabilir. Bununla birlikte, uzun vadeli etkinli\u011fini ve g\u00fcvenli\u011fini do\u011frulamak ve en uygun tedavi plan\u0131n\u0131 ve dozaj\u0131n\u0131 belirlemek i\u00e7in daha fazla ara\u015ft\u0131rmaya ihtiya\u00e7 vard\u0131r.<\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

Study on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice Diabetes nephropathy (DN) is one of the most common microvascular complications in diabetes patients. The damage to renal function caused by DN is one of the major causes of disability and death worldwide. Despite some progress in the treatment of DN […]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"yoast_head":"\nStudy on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice - China Chemical Manufacturer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/longchangextracts.com\/tr\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Study on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice - China Chemical Manufacturer\" \/>\n<meta property=\"og:description\" content=\"Study on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice Diabetes nephropathy (DN) is one of the most common microvascular complications in diabetes patients. The damage to renal function caused by DN is one of the major causes of disability and death worldwide. Despite some progress in the treatment of DN […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/longchangextracts.com\/tr\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/\" \/>\n<meta property=\"og:site_name\" content=\"China Chemical Manufacturer\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-02T16:40:09+00:00\" \/>\n<meta name=\"author\" content=\"longcha9\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"longcha9\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/\",\"url\":\"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/\",\"name\":\"Study on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice - China Chemical Manufacturer\",\"isPartOf\":{\"@id\":\"https:\/\/longchangextracts.com\/#website\"},\"datePublished\":\"2024-08-02T16:40:09+00:00\",\"dateModified\":\"2024-08-02T16:40:09+00:00\",\"author\":{\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869\"},\"breadcrumb\":{\"@id\":\"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/longchangextracts.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Study on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/longchangextracts.com\/#website\",\"url\":\"https:\/\/longchangextracts.com\/\",\"name\":\"China Chemical Manufacturer\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/longchangextracts.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869\",\"name\":\"longcha9\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/longchangextracts.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g\",\"caption\":\"longcha9\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ganoderma Polisakkaritinin Diyabet Nefropatili Fareler \u00dczerindeki \u0130yile\u015ftirici Etkisi ve Mekanizmas\u0131 \u00dczerine \u00c7al\u0131\u015fma - \u00c7in Kimya \u00dcreticisi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/longchangextracts.com\/tr\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/","og_locale":"tr_TR","og_type":"article","og_title":"Study on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice - China Chemical Manufacturer","og_description":"Study on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice Diabetes nephropathy (DN) is one of the most common microvascular complications in diabetes patients. The damage to renal function caused by DN is one of the major causes of disability and death worldwide. Despite some progress in the treatment of DN […]","og_url":"https:\/\/longchangextracts.com\/tr\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/","og_site_name":"China Chemical Manufacturer","article_published_time":"2024-08-02T16:40:09+00:00","author":"longcha9","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"longcha9","Tahmini okuma s\u00fcresi":"9 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/","url":"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/","name":"Ganoderma Polisakkaritinin Diyabet Nefropatili Fareler \u00dczerindeki \u0130yile\u015ftirici Etkisi ve Mekanizmas\u0131 \u00dczerine \u00c7al\u0131\u015fma - \u00c7in Kimya \u00dcreticisi","isPartOf":{"@id":"https:\/\/longchangextracts.com\/#website"},"datePublished":"2024-08-02T16:40:09+00:00","dateModified":"2024-08-02T16:40:09+00:00","author":{"@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869"},"breadcrumb":{"@id":"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/longchangextracts.com\/ganoderma-lucidum-polysaccharide-diabetic-nephropathy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/longchangextracts.com\/"},{"@type":"ListItem","position":2,"name":"Study on the Improvement Effect and Mechanism of Ganoderma Polysaccharide on diabetes Nephropathy Mice"}]},{"@type":"WebSite","@id":"https:\/\/longchangextracts.com\/#website","url":"https:\/\/longchangextracts.com\/","name":"\u00c7in Kimyasal \u00dcreticisi","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/longchangextracts.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/80933ac6926ad63fea74ec33f8d04869","name":"longcha9","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/longchangextracts.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c1e84ee0759373263198c58e8f338f80?s=96&d=mm&r=g","caption":"longcha9"}}]}},"_links":{"self":[{"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/posts\/3667"}],"collection":[{"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/comments?post=3667"}],"version-history":[{"count":1,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/posts\/3667\/revisions"}],"predecessor-version":[{"id":3675,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/posts\/3667\/revisions\/3675"}],"wp:attachment":[{"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/media?parent=3667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/categories?post=3667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/longchangextracts.com\/tr\/wp-json\/wp\/v2\/tags?post=3667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}